Clinical Trials
3 trialsNCT00093990 2016-09-14
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00354146 2011-02-01
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00048503 2010-04-27
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed